Evoked potential studies in the antiphospholipid syndrome: Differential diagnosis from multiple sclerosis

Annals of the Rheumatic Diseases

Volumn 65, Issue 4, 2006, Pages 525-528

  Paran, Daphna ^a,b   Chapman, J ^a   Korczyn, A D ^a   Elkayam, O ^b   Hilkevich, O ^a   Groozman, G B ^a   Levartovsky, D ^b   Litinsky, I ^b   Caspi, D ^b   Segev, Y ^a   Drory, V E ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HEADACHE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BRAIN; DIAGNOSIS, DIFFERENTIAL; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; GALVANIC SKIN RESPONSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 33645117342     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.040352     Document Type: Article

References (30)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:480-9.
2. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
3. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311.
4. Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119-24.
5. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine 1997;76:203-12.
6. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and significance of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997;103:33-7.
7. Menon S, Janeson-Shotall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:728-34.
8. Brey RL, Gharavi AE, Lockshin MD. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am 1993;4:833-50.
9. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine 2000;79:57-68.
10. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
11. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine 1993;72:113-24.
12. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
13. Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000;14:259-65.
14. Molad Y, Sidi Y, Gornish M, Lerner M, Pinkhas J, Weinberger A. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J Rheumatol 1992;19:556-61.
15. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
16. Aminoff MJ, Davis SL, Panitch HS. Serial evoked potentials studies in patients with definite multiple sclerosis. Clinical relevance. Arch Neurol 1984;41:1197-202.
17. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. Applications to planning and interpretation of clinical therapeutic trials. Brain, 1991;114;1057-67.
18. Drory VE, Nisipeanu P, Korczyn AD. Tests of autonomic dysfunction in patients with multiple sclerosis. Acta Neurol Scand 1995;92:356-60.
19. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
20. Ijdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, et al. Antiphospholipid antibodies in patients with multiple sclerosis and MS-like illnesses. Lupus 1999;8:109-15.
21. Sastre-Garriga J, Reverter JC, Font J, Tintore M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a non-selected large group of patients with multiple sclerosis. Ann Neurol 2001;49:408-11.
22. Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry 2002;72:647-9.
23. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 1998;44:629-34.
24. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003;42:200-13.
25. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57.
26. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
27. Leary SM, Davie CA, Parker GJ, Stevenson VL, Wang L, Barker GJ, et al. 1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999;246:1023-6.
28. Assaf Y, Ben-Bashat D, Chapman J, Peled S, Biton IE, Kafri M, et al. High b-value q-space analyzed diffusion-weighted MRI: application to multiple sclerosis. Magn Reson Med 2002;47:115-26.
29. Rovaris M, Viti B, Ciboddo G, Gerevini S, Capra R, Iannucci G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry 2000;68:170-7.
30. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8:127-33.